5-heptadecylresorcinol profile

5-heptadecylresorcinol : A 5-alkylresorcinol that is resorcinol which is substituted by a heptadecyl group at position 5. It is found in wheat bran. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	181700
CHEMBL ID	497530
CHEBI ID	145967
SCHEMBL ID	1914183

Synonym
5-heptadecylbenzene-1,3-diol
CHEMBL497530
1,3-dihydroxy-5-n-heptadecylbenzene
CHEBI:145967
5-heptadecyl-1,3-dihydroxybenzene
5-heptadecyl-1,3-benzenediol
41442-57-3
5-n-heptadecylresorcinol
5-heptadecylresorcinol
unii-mxe8zpj5xe
mxe8zpj5xe ,
1,3-benzenediol, 5-heptadecyl-
SCHEMBL1914183
AKOS022184647
LMPK15030003
5-heptadecylresorcinol, analytical standard
DTXSID50920522
FS-9410
1,3-dihydroxy-5-heptadecylbenzene
AMY37952
5-heptadecyl-1,3-benzenediol; 1,3-dihydroxy-5-heptadecylbenzene; 5-heptadecylresorcinol
1,3-dihydroxy-5-heptadecylbenzen;
A873058
CS-0023110
HY-N2673

Excerpt	Reference	Relevance
" However, the low bioavailability of AR-C17 due to its low water solubility restricts its application."	( Quercetin Enhances the Availability of 5-Heptadecylresorcinol by Inhibiting the Expression of P-gp. Fan, M; Jiang, L; Li, Y; Pan, W; Qian, H; Wang, L; Zhang, K, 2023)	1.18

Role	Description
antineoplastic agent	A substance that inhibits or prevents the proliferation of neoplasms.
plant metabolite	Any eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
5-alkylresorcinol	A resorcinol compound having an alkyl substituent at the 5-position.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (6)

Assay ID	Title	Year	Journal	Article
AID376620	Antimicrobial activity against Candida albicans ATCC 90028 by broth dilution method	2006	Journal of natural products, Apr, Volume: 69, Issue:4	5-alkylresorcinols from Merulius incarnatus.
AID604333	Growth inhibition of human HCT116 cells after 48 hrs by MTT assay	2011	Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13	5-alk(en)ylresorcinols as the major active components in wheat bran inhibit human colon cancer cell growth.
AID376623	Antimicrobial activity against Aspergillus fumigatus ATCC 90906 by broth dilution method	2006	Journal of natural products, Apr, Volume: 69, Issue:4	5-alkylresorcinols from Merulius incarnatus.
AID376621	Antimicrobial activity against Candida glabrata ATCC 90030 by broth dilution method	2006	Journal of natural products, Apr, Volume: 69, Issue:4	5-alkylresorcinols from Merulius incarnatus.
AID376622	Antimicrobial activity against Candida krusei ATCC 6258 by broth dilution method	2006	Journal of natural products, Apr, Volume: 69, Issue:4	5-alkylresorcinols from Merulius incarnatus.
AID604334	Growth inhibition of human HT-29 cells after 48 hrs by MTT assay	2011	Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13	5-alk(en)ylresorcinols as the major active components in wheat bran inhibit human colon cancer cell growth.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (10.00)	29.6817
2010's	1 (10.00)	24.3611
2020's	8 (80.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	10 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
ciprofloxacin Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.	2.03	1	aminoquinoline; cyclopropanes; fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone; zwitterion	antibacterial drug; antiinfective agent; antimicrobial agent; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; environmental contaminant; topoisomerase IV inhibitor; xenobiotic
pentamidine Pentamidine: Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.. pentamidine : A diether consisting of pentane-1,5-diol in which both hydroxyl hydrogens have been replaced by 4-amidinophenyl groups. A trypanocidal drug that is used for treatment of cutaneous leishmaniasis and Chagas disease.	2.03	1	aromatic ether; carboxamidine; diether	anti-inflammatory agent; antifungal agent; calmodulin antagonist; chemokine receptor 5 antagonist; EC 2.3.1.48 (histone acetyltransferase) inhibitor; NMDA receptor antagonist; S100 calcium-binding protein B inhibitor; trypanocidal drug; xenobiotic
s-adenosylmethionine acylcarnitine: structure in first source. S-adenosyl-L-methioninate : A sulfonium betaine that is a conjugate base of S-adenosyl-L-methionine obtained by the deprotonation of the carboxy group.	2.6	1	sulfonium betaine	human metabolite
adipostatin a adipostatin A: allergen from cashew nut shell oil; as adipostatin found as inhibitor of glycerol-3-phosphate dehydrogenase from Streptomyces; Also found in bees; do not confuse with cardol, RN 57486-25-6, MF unknown;. cardol : Resorcinol substituted at position 5 by a pentadecyl chain.	2.45	2	5-alkylresorcinol	EC 1.1.5.3 (glycerol-3-phosphate dehydrogenase) inhibitor
quercetin [no description available]	7.6	1	7-hydroxyflavonol; pentahydroxyflavone	antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger
amphotericin b Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.. amphotericin B : A macrolide antibiotic used to treat potentially life-threatening fungal infections.	2.03	1	antibiotic antifungal drug; macrolide antibiotic; polyene antibiotic	antiamoebic agent; antiprotozoal drug; bacterial metabolite
bilobol bilobol: structure given in first source; RN given refers to (Z)-isomer; RN for cpd without isomeric designation not avail 6/90	2.03	1	5-alkenylresorcinol

Condition	Relationship Strength	Studies
Cancer of Colon [description not available]	2.06	1
Colonic Neoplasms Tumors or cancer of the COLON.	2.06	1
Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).	3.22	3
Atherogenesis [description not available]	2.41	1
Atheroma [description not available]	2.41	1
Atherosclerosis A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.	7.41	1
Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.	7.6	1
Insulin Sensitivity [description not available]	2.6	1
Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.	7.6	1
Cognitive Decline [description not available]	2.25	1
Acute Confusional Senile Dementia [description not available]	2.25	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.25	1
Astrocytosis [description not available]	2.25	1
Innate Inflammatory Response [description not available]	2.25	1
Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)	2.25	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	7.25	1
Cognitive Dysfunction Diminished or impaired mental and/or intellectual function.	2.25	1

5-heptadecylresorcinol

Description

Cross-References

Synonyms (25)

Research Excerpts

Bioavailability

Roles (2)

Drug Classes (1)

Bioassays (6)

Research

Studies (10)

Market Indicators

Research Demand Index: 13.00

Study Types

5-heptadecylresorcinol

Description

Cross-References

Synonyms (25)

Research Excerpts

Bioavailability

Roles (2)

Drug Classes (1)

Bioassays (6)

Research

Studies (10)

Market Indicators

Research Demand Index: 13.00

Study Types

Related Drugs (7)

Related Conditions (17)